CAM-PaC will provide an armamentarium of novel and validated therapeutic targets, compounds and predictive tools that are expected to improve survival and reduce suffering of PDAC patients.

Furthermore, CAM-PaC as an SME-targeted consortium includes four research-intensive biotechnologies SME that will be provided with the possibility to develop and expand their portfolios of methods, applications and assays in a clinically meaningful context where the need for patients is compelling. It is anticipated that CAM-PaC will improve the competitiveness of participating SME on the European and International market.